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(mean age: 16 years) than patients in our study (24 years). Mean course of the disease in our patients could thus be longer. In the younger patients from our sample (Ͻ 20 years, n = 16), the S frequency was 41%, similar to the non AN groups, whereas in the older (Ն 20 years, n = 51), the S frequency was 55%, which indicates that the S allele could predispose to a protracted course of AN.
There is a great consistency between our results and the in vitro effects of the S allele. 2 The effects of the S allele are quite similar to that of serotonergic anorectic drugs inhibiting reuptake of the 5-HT. However, the effects observed here may be secondary to behavioral or psychological traits possibly associated with this polymorphism.
Major corrections are indicated for 'Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia'
SIR -We are writing to point out major corrections of Edgar et al 1 which affect the conclusions of the authors. Edgar et al 1 identify four proteins, based on partial protein sequence, isoelectric point, and molecular weight, which appear to be expressed at different amounts in schizophrenia brains vs normal brains, specifically in the hippocampus. The authors' key conclusion regarding localization of the proteins which they identified is that three of the four localize to chromosome 6q, a result which they calculate to be significant at the P = 0.002 level.
We have disagreements with Edgar et al 1 in three main areas:
(1) The number of their isolated proteins which map to chromosome 6q: Edgar et al 1 identifies one of these three proteins as diazepam binding inhibitor (DBI) and note it to map to 6q12-q21 on an inconsistent basis via OMIM. This is indeed listed as one of the two loci for DBI (OMIM 125950), the other one being 2q12-q21. However, in the first paragraph of the text of the OMIM entry for DBI, this inconsistency is explained. The functional gene for DBI indeed resides on 2q12-q21, but a pseudogene named DBIL2 resides on 6q12-q21 via a careful study by Gersuk et al. 2 The authors 2 cite several lines of evidence indicating that DBIL2 is a pseudogene: (1) it lacks introns predicted from other species; (2) a one base pair deletion in the potential coding region which is in an important functional domain results in a framshift and a resultant premature stop codon; (3) its homology to the functional DBI is restricted to the transcribed region with quite sharp boundaries suggesting DBIL2 arose by means of genomic integration of a processed message since very little of the expected 5Ј or 3ЈUTRs (untranslated regions) predicted by homology comparisons to other species (and the human functional DBI) are present; (4) it is flanked by direct repeats which is a characteristic of processed pseudogenes; 3 and (5) it has no detectable RNA transcript. 2 Finally, the authors explain why a previous study 4 placed DBI on 6q12-q21: their antisense PCR primer would have been interrupted by an intron in the functional gene, but not in the pseudogene. 2 Edgar et al 1 refer to their earlier paper 5 to describe the identification process for a spot on their twodimensional electrophoresis (2DE) gels which appeared decreased in concentration in schizophrenic hippocampi compared to normal controls. After recovery from a preparative 2DE gel, the protein was subjected to trypsin digestion and one of the peptides was determined by N-terminal sequencing to have the sequence of TKPSDEEM. 5 It was not explained why trypsin, which cleaves after (on the carboxyl side) of lysine (K) and arginine (R) residues no matter the size, failed to cleave after the lysine in this fragment, although it is likely that this is due to a proline (P) residue on the carboxyl side of this lysine. 6 Still, this sequence of amino acids is indeed found to be identical to residues 18 through 25 of the functional DBI (GenBank M15887), and this peptide is immediately preceded by a lysine residue in the intact protein.
However, even if DBIP1 were expressed, the residues at this site would be TKPGDDEM as predicted from the nucleotide sequence (GenBank L27274), and this is different from what was found at two of the eight residues by Edgar et al. 5 Hence, the spot identified by Edgar et al 5 is indeed DBI, the functional version, however, this gene is located on 2q12-q21.
The statistics used to analyze their results: Since this correction means that now two of the four genes identified through proteome analysis are located on chromosome 6q, the probability calculations must be adjusted. Edgar et al 1 originally calculated their probability using the assumption of 44 autosomal arms and one sex chromosome, and equal numbers of genes on each of these 45 locations. Thus, their calculation of the likelihood that out of four genes chosen at random, that three of them would reside on the same chromosomal arm (or the X chromosome) was as follows: 2) A larger error is the assumption of equal sizes among the autosomal chromosomal arms and the X chromosome. The chromosome 6 sequencing center at The Sanger Centre estimates that chromosome 6q contains approximately 61% of the total amount of the chromosome. NCBI estimates the human genome to consist of 3 175 491 000 bp of euchromatic sequence, and chromosome 6 to account for approximately 183 000 000 bp of this total. Taking into account the above information, the proportion of the human genome encompassed by 6q is approximately: 0.61 × 183 000 000/3 175 491 000 = 0.035, or essentially 1/29. This is to be contrasted with 1/45 = 0.022, the estimate used in this paper. None of the above calculations actually take into account the close proximity of the two 6q genes (SOD2 and TCP1). SOD2 has been mapped to 6q25.3 by a combination of fluorescence in situ hybridization (FISH) and a somatic cell hybrid panel containing different segments of chromosome six, 7 and TCP1 has been mapped to 6q25.3-q26 by FISH. 8 The 6q25.3-q26 region is estimated to encompass no more than 4.5% of the total amount of the chromosome 6 by The Sanger Centre. Hence, this part of the genome, 6q25. 3) The plausibility of the pathophysiological hypotheses to explain their findings: After the various corrections which we suggest, the results nevertheless, remain nominally significant at the P = 0.016 level for implicating chromosome 6q25.3-q26 as containing more genes of altered expression than expected by chance via the proteome analysis of Edgar et al. 1 Leaving aside any other methodological limitations inherent to proteomics, which is a field of inquiry still in its infancy (reviewed in Blackstock et al 9 ) , potential explanations for their observations include the pathophysiological connections speculated upon by Edgar et al 1 that susceptibility to damage from reactive oxygen species is greater in the schizophrenic hippocampus (presumably due in part to decreased SOD2 levels) resulting in an increased turnover of neuronal interconnections (resulting in part in increased TCP1 levels as would be expected with increased cytoskeletal turnover). 1 This scenario would, however, not take into account the close proximity of the two genes, ie, their positional relationships. The next proposal of Edgar et al 1 seemingly takes this into account: that both SOD2 and TCP1 are within the t complex of genes, which has been shown to be able to maintain other deleterious genes in mice by means of segregation distortion. 10 However, if the reason for this segregation distortion is SOD2 as is proposed, 11 two problems arise. First, this would seem contradictory in the sense that sperm motility would be more likely to suffer than improve (which it would need to do to maintain the proposed segregation distortion) with decreased SOD2 levels, as found in schizophrenic hippocampi. 1 Second, if SOD2 is the cause of the segregation distortion (and not a combination of SOD2 and TCP1), then one is again in the situation of not taking into account the close proximity of the two genes, ie, their positional relationships. The remaining possibility is that there is a schizophrenia susceptibility gene different from, but located very near SOD2 and TCP1, and the latter two genes might be serving as biological markers of a sort for the actual susceptibility gene in the region. Of course, a replication of Edgar et al's findings 1 will be crucial prior to accepting the implication of the region of 6q25.3-q26 as harboring a schizophrenia susceptibility gene by means of proteomics. The primary support for a schizophrenia susceptibility gene in 6q13-q26 remains the linkage mapping results, which have been reported as positive in several different family samples, [12] [13] [14] including a combined analysis of more than 1000 affected sibling pairs. 
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Edgar replies
SIR -The authors, Sanders and Gejman, suggest that major corrections are indicated for 'Comparative proteome analysis of the hippocampus implicates chromosome 6q in schizophrenia' on the basis that the functional gene location for DBI is on chromosome 2q rather than 6q. At the time of acceptance of the manuscript the OMIM database listed the functional DBI gene loci as '6q but inconsistent', see Table 2 of the paper. However, their correction does not affect the conclusions of the paper. In their own words '..we agree that their (Edgar et al) proteomic experiment points to 6q25.3-q26 as a chromosomal region with an increased likelihood of containing a gene involved in the etiology of schizophrenia...'. The other prime conclusion of the paper, which is not questioned, is that the proteins DBI, TCP-1, SOD-2 and CRMP are significantly altered in concentration in a set of post mortem schizophrenic hippocampi when compared to a control set.
A purpose of the authors is revealed in the final paragraph when they state 'the primary support for a schizophrenia susceptibility gene in 6q13-q26 remains linkage mapping results'. Results, to which the authors themselves have contributed. However, it is well known that linkage mapping results point to a plethora of possible susceptibility loci, on a multitude of chromosomes. Although proteomics, as they suggest, is in 'its infancy' our work is the first proteomic pointer towards a schizophrenia susceptibility loci. We suggest that a combination of proteomics and linkage mapping results together will prove helpful in identifying valid loci, one of which may be 6q25.3-q26.
